Evidence map›Paper›PMID 28339485›Full record

ArticlePloS one2017

Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.

Krisztian Eros, Klara Magyar, Laszlo Deres, Arpad Skazel, Adam Riba, Zoltan Vamos, Tamas Kalai, Ferenc Gallyas, Balazs Sumegi, Kalman Toth and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. PARP-1 and SIRT-1 are Interacted in Diabetic Nephropathy by Activating AMPK/PGC-1α Signaling Pathway.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. PARP-1 (Poly[ADP-Ribose] Polymerase-1).Hypertension (Dallas, Tex. : 1979) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Krisztian Eros1st Department of Medicine, Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Klara Magyar1st Department of Medicine, Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Laszlo Deres1st Department of Medicine, Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Arpad Skazel1st Department of Medicine, Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Adam Riba1st Department of Medicine, Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Zoltan VamosSzentagothai Research Centre, University of Pecs, Pecs, Baranya, Hungary.
Tamas KalaiDepartment of Organic and Pharmacological Chemistry, Medical School, University of Pecs, Pecs, Baranya, Hungary.
Ferenc GallyasSzentagothai Research Centre, University of Pecs, Pecs, Baranya, Hungary.
Balazs SumegiSzentagothai Research Centre, University of Pecs, Pecs, Baranya, Hungary.
Kalman Toth1st Department of Medicine, Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.
Robert Halmosi1st Department of Medicine, Clinical Centre, University of Pecs, Pecs, Baranya, Hungary.ORCID http://orcid.org/0000-0002-6965-7743
University of Pecs · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular remodeling during chronic hypertension may impair the supply of tissues with oxygen, glucose and other compounds, potentially unleashing deleterious effects. In this study, we used Spontaneously Hypertensive Rats and normotensive Wistar-Kyoto rats with or without pharmacological inhibition of poly(ADP-ribose)polymerase-1 by an experimental compound L-2286, to evaluate carotid artery remodeling and consequent damage of neuronal tissue during hypertension. We observed elevated oxidative stress and profound thickening of the vascular wall with fibrotic tissue accumulation induced by elevated blood pressure. 32 weeks of L-2286 treatment attenuated these processes by modulating mitogen activated protein kinase phosphatase-1 cellular levels in carotid arteries. In hypertensive animals, vascular inflammation and endothelial dysfunction was observed by NF-κB nuclear accumulation and impaired vasodilation to acetylcholine, respectively. Pharmacological poly(ADP-ribose)polymerase-1 inhibition interfered in these processes and mitigated Apoptosis Inducing Factor dependent cell death events, thus improved structural and functional alterations of carotid arteries, without affecting blood pressure. Chronic poly(ADP-ribose)polymerase-1 inhibition protected neuronal tissue against oxidative damage, assessed by nitrotyrosine, 4-hydroxinonenal and 8-oxoguanosine immunohistochemistry in the area of Cornu ammonis 1 of the dorsal hippocampus in hypertensive rats. In this area, extensive pyramidal cell loss was also attenuated by treatment with lowered poly(ADP-ribose)polymer formation. It also preserved the structure of fissural arteries and attenuated perivascular white matter lesions and reactive astrogliosis in hypertensive rats. These data support the premise in which chronic poly(ADP-ribose)polymerase-1 inhibition has beneficial effects on hypertension related tissue damage both in vascular tissue and in the hippocampus by altering signaling events, reducing oxidative/nitrosative stress and inflammatory status, without lowering blood pressure.

Indexed as

AnimalsBlood PressureCarotid ArteriesHippocampusHypertensionMaleOxidative StressPiperidinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsQuinazolinesRatsRats, Inbred SHRRats, Inbred WKYVascular Remodeling2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-onePiperidinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsQuinazolines

Identifiers

PMID28339485
PMCPMC5365133
OpenAlexW2600449517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.